Lessons for Parkinson’s From Multiple Sclerosis

In the world of neurology, conditions like Parkinson’s and Multiple Sclerosis (MS) are often studied in isolation, yet they share a complex biological landscape that offers fertile ground for mutual learning. A fascinating discussion between Dr Indu Subramanian and Professor Lorraine Kalia explores how the successes in MS research might provide a much-needed roadmap for breakthroughs in treating Parkinson’s, particularly regarding the elusive goal of disease-modifying therapies. Professor Kalia recalls a pivotal shift in her own career, noting that while MS treatments were advancing rapidly during her medical training, Parkinson’s research seemed to lag behind. This disparity inspired a unique gathering of experts from both fields in Toronto to identify where Parkinson’s could adopt successful strategies from MS and, perhaps surprisingly, where the Parkinson’s community is actually leading the way. One of the most significant takeaways from the MS success story is the mastery of managing inflammation. Nearly all current MS treatments are designed to target the immune system’s role in the condition. As we increasingly understand the role of inflammation and the immune system in Parkinson’s, there is a clear opportunity to adapt these established methodologies to slow or even stop the progression of the condition. A key driver of MS research success has been the use of robust neuroimaging biomarkers, such as MRI, to track the condition's progress. In Parkinson’s, we are still working towards developing similarly reliable biomarkers that go beyond clinical observations. Establishing these early markers is essential for moving away from traditional clinical trials and towards more sensitive measures that can prove a treatment is truly changing the course of the condition. There is also a growing emphasis on the "prodomal" or early stages of these conditions. In MS, there is already "proof in the pudding" that treating people at the very earliest signs leads to better long-term outcomes. While this has long been a theoretical goal in Parkinson’s, the MS model provides the evidence needed to push for earlier detection and intervention strategies. Interestingly, the learning is not entirely one-sided. While MS has seen a flurry of pharmaceutical successes, the Parkinson’s community has pioneered a more holistic, patient-centered approach to lifestyle management. Professor Kalia notes that the Parkinson’s field has arguably been more successful in embracing the importance of physical activity, diet, sleep, and mindfulness. As MS research continues to evolve, it may look to the Parkinson’s model to better integrate these wellness strategies alongside traditional pharmacological care.